Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
CardiomyopathiesHeart Failure
Interventions
DEVICE

Heart Rate Monitor Enhanced Treatment Optimization

Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.

Trial Locations (4)

25304

TERMINATED

CAMC, Charleston

45242

RECRUITING

TriHealth Hatton Research Institute, Cincinnati

75020

RECRUITING

CardioVoyage, McKinney

77339

TERMINATED

Texas Cardiology Associates of Houston, Kingwood

All Listed Sponsors
lead

Zoll Medical Corporation

INDUSTRY